Christopher Chen
Stock Analyst at Robert W. Baird
(3.22)
# 2,544
Out of 4,662 analysts
5
Total ratings
75%
Success rate
55.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Maintained: Buy | $28 → $52 | $35.11 | +48.11% | 2 | Aug 18, 2026 | |
| LRMR Larimar Therapeutics | Maintained: Buy | $5 | $4.06 | +23.15% | 1 | Jun 30, 2026 | |
| DFTX Definium Therapeutics | Maintained: Buy | $37 → $57 | $46.18 | +23.43% | 2 | Jun 23, 2026 |
Amylyx Pharmaceuticals
Aug 18, 2026
Maintained: Buy
Price Target: $28 → $52
Current: $35.11
Upside: +48.11%
Larimar Therapeutics
Jun 30, 2026
Maintained: Buy
Price Target: $5
Current: $4.06
Upside: +23.15%
Definium Therapeutics
Jun 23, 2026
Maintained: Buy
Price Target: $37 → $57
Current: $46.18
Upside: +23.43%